TriSalus Life Sciences
Update in progressTLSI (NasdaqGM)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryMedical Devices
TriSalus Life Sciences develops and commercializes drug delivery technology and immuno-oncology therapies to improve outcomes for patients with hard-to-treat liver and pancreatic cancers in the United States. Its Pressure-Enabled Drug Delivery platform includes the TriNav infusion system used in liver tumor embolization, plus a Pancreatic Retrograde Venous Infusion device in Phase 1. It also develops nelitolimod in Phase 1 for multiple cancers. Founded 2009, based in Westminster, Colorado.
Company score
- Sentiment
- 0.02
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.07
- Governance
- -0.14
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- -0.01
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.00
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Sort by
Order by
Timeframe
No news articles are available for this company yet.
Unable to load company news.
Loading more news
You're all caught up!